Zhang Lu, Luo Xiaoning, Mo Xiaokai, Huang Wenhui, Liang Changhong, Zhang Shuixing
Graduate College, Second School of Clinical Medicine, Southern Medical University, Guangzhou 510515, China.
Department of Radiology, Guangdong Academy of Medical Sciences/Guangdong General Hospital, Guangzhou 510282, China.
Nan Fang Yi Ke Da Xue Xue Bao. 2018 Dec 30;38(12):1459-1464. doi: 10.12122/j.issn.1673-4254.2018.12.10.
To develop a model based on the clinical variables for evaluating the risk of distant metastasis in patients with advanced nasopharyngeal carcinoma (NPC).
From September,2007 to June,2015,a total of 238 consecutive patients with biopsy-proven NPC in stage Ⅲ-Ⅳ(M0) based on the AJCC TNM staging manual were enrolled in this study,including 106 male and 34 female patients with a median age of 45 years (range 18-68 years).In this cohort,126 patients received concurrent chemoradiotherapy,and 24 received chemotherapy and radiotherapy,and 40 had induction chemotherapy.We used the least absolute shrinkage and selection operator (LASSO) method to select the most significant features for establishing the model for assessing the risks of distant metastasis.
Among the 18 clinical variables tested,5 were significantly associated with distant metastasis in advanced NPC,including plasma Epstein-Barr virus (EBV) DNA,neutrophil/lymphocytes (NLR),VCA-IgA,concurrent chemoradiotherapy,and induction chemotherapy.Based on these 5 clinical variables,we established the following model:risk score=1.73×EBV DNA+0.54×NLR+0.38×VCA-IgA-0.95×concurrent chemoradiotherapy-2.37×induction chemotherapy+0.51.The cutoff point of this model was-0.62,which classified the patients into high-risk and low-risk groups for distant metastasis.This model showed a good performance in predicting distant metastasis in patients with advanced NPC (<0.01).
The model we established herein can be used for evaluating the risks of distant metastasis in patients with advanced NPC and provides assistance in the clinical decision-making on individualized treatment strategy.
建立一种基于临床变量的模型,用于评估晚期鼻咽癌(NPC)患者远处转移的风险。
2007年9月至2015年6月,本研究共纳入238例经活检证实为Ⅲ-Ⅳ期(M0)的NPC患者,依据美国癌症联合委员会(AJCC)TNM分期手册,其中男性106例,女性34例,中位年龄45岁(范围18-68岁)。在该队列中,126例患者接受同步放化疗,24例接受化疗和放疗,40例接受诱导化疗。我们使用最小绝对收缩和选择算子(LASSO)方法选择最显著特征,以建立评估远处转移风险的模型。
在测试的18个临床变量中,5个与晚期NPC的远处转移显著相关,包括血浆EB病毒(EBV)DNA、中性粒细胞/淋巴细胞(NLR)、VCA-IgA、同步放化疗和诱导化疗。基于这5个临床变量,我们建立了以下模型:风险评分=1.73×EBV DNA+0.54×NLR+0.38×VCA-IgA-0.95×同步放化疗-2.37×诱导化疗+0.51。该模型的截断点为-0.62,据此将患者分为远处转移的高风险和低风险组。该模型在预测晚期NPC患者的远处转移方面表现良好(<0.01)。
我们在此建立得模型可用于评估晚期NPC患者远处转移的风险,并为个体化治疗策略的临床决策提供帮助。